Scientists track rare bone cancer to unlock future treatments
NCT ID NCT03910465
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 6 times
Summary
This study follows 300 children and adults with chordoma, a rare bone cancer of the skull base or spine. Researchers will track how the disease progresses over time using imaging, physical exams, and surveys. The goal is to better understand chordoma's behavior to design more effective future treatments and supportive care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could provide crucial insights into chordoma's behavior, helping design better treatments and supportive care for patients.
- What could go wrong
- This is an observational study, not testing a new treatment. It may not directly lead to new therapies, and results depend on participant follow-up.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHORDOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill stall advanced sarcomas?
- How do patients feel after Nose-Based brain surgery? new study aims to find out
- New drug shows promise for rare spine cancer
- New gene therapy offers hope for advanced cancers
- Targeted drug shows promise for rare bone cancer
- New proton therapy could shrink skull tumor treatment to just 5 days